These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 17584318)

  • 1. Efficacy and safety of preprandial versus postprandial administration of low-dose cyclosporin microemulsion (Neoral) in patients with psoriasis vulgaris.
    Hashizume H; Ito T; Yagi H; Takigawa M; Kageyama H; Furukawa F; Hata M; Shirahama S; Tanaka M; Higashishiba T; Machida H; Tsushima T; Matsushita K
    J Dermatol; 2007 Jul; 34(7):430-4. PubMed ID: 17584318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preprandial vs. postprandial pharmacokinetics of cyclosporine in patients with psoriasis.
    Umezawa Y; Mabuchi T; Ozawa A
    Int J Dermatol; 2007 Aug; 46(8):880-2. PubMed ID: 17651179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of a fixed-dose cyclosporin microemulsion (100 mg) for the treatment of psoriasis.
    Shintani Y; Kaneko N; Furuhashi T; Saito C; Morita A
    J Dermatol; 2011 Oct; 38(10):966-72. PubMed ID: 21545506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of two cyclosporine dosage regimens for the treatment of severe psoriasis.
    Yoon HS; Youn JI
    J Dermatolog Treat; 2007; 18(5):286-90. PubMed ID: 17852632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intermittent vs. continuous 1-year cyclosporin use in chronic plaque psoriasis.
    Chaidemenos GC; Mourellou O; Avgoustinaki N; Papakonstantinou M; Karakatsanis G; Katsambas A
    J Eur Acad Dermatol Venereol; 2007 Oct; 21(9):1203-8. PubMed ID: 17894706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefits of cyclosporine absorption profiling in nephrotic syndrome: preprandial once-daily administration of cyclosporine microemulsion improves slow absorption and can standardize the absorption profile.
    Takeda A; Horike K; Onoda H; Ohtsuka Y; Yoshida A; Uchida K; Morozumi K
    Nephrology (Carlton); 2007 Apr; 12(2):197-204. PubMed ID: 17371346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study.
    Ho VC; Griffiths CE; Berth-Jones J; Papp KA; Vanaclocha F; Dauden E; Beard A; Puvanarajan L; Paul C
    J Am Acad Dermatol; 2001 Apr; 44(4):643-51. PubMed ID: 11260540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacious treatment of psoriasis with low-dose and intermittent cyclosporin microemulsion therapy.
    Ito T; Furukawa F; Iwatsuki K; Matsue H; Shimada S; Takigawa M; Tokura Y
    J Dermatol; 2014 May; 41(5):377-81. PubMed ID: 24628433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal time for therapeutic drug monitoring of cyclosporine microemulsion in patients with psoriasis.
    Umezawa Y; Ozawa A
    Int J Dermatol; 2007 Jul; 46(7):763-6. PubMed ID: 17614813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the bioequivalence of single 100-mg doses of two oral formulations of cyclosporin A microemulsion: a randomized, open-label, two-period crossover study in healthy adult male Mexican volunteers.
    Piñeyro-López A; Piñeyro-Garza E; Torres-Alanís O; Reyes-Araiza R; Gómez-Silva M; Waksman N; E Salazar-Leal M; Luján-Rangel R
    Clin Ther; 2007 Sep; 29(9):2049-54. PubMed ID: 18035203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative non randomized study of narrow-band (NB) (312 +/- 2 nm) UVB phototherapy versus sequential therapy with oral administration of low-dose Cyclosporin A and NB-UVB phototherapy in patients with severe psoriasis vulgaris.
    Calzavara-Pinton P; Leone G; Venturini M; Sala R; Colombo D; La Parola IL; Sitzia N; Ferraro C; Picardo M
    Eur J Dermatol; 2005; 15(6):470-3. PubMed ID: 16280301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daily versus intermittent application of high-concentration tacalcitol ointment in combination with low-dose cyclosporin for psoriasis vulgaris.
    Abe M; Syuto T; Hasegawa M; Sogabe Y; Yokoyama Y; Ishikawa O
    J Dermatol; 2006 Feb; 33(2):108-11. PubMed ID: 16556277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical experience with the use of cyclosporin A in psoriasis. Results of a retrospective study.
    Ojeda R; Sánchez Regaña M; Massana J; Oliete R; Umbert P
    J Dermatolog Treat; 2005; 16(4):238-41. PubMed ID: 16249146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical usefulness and patient satisfaction for treatment with low-dose cyclosporin administration in patients with moderate psoriasis vulgaris.
    Abe M; Ishibuchi H; Syuto T; Sogabe Y; Yokoyama Y; Ishikawa O
    J Dermatol; 2007 May; 34(5):290-3. PubMed ID: 17408436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costs of treatment in patients with moderate to severe plaque psoriasis: economic analysis in a randomized controlled comparison of methotrexate and cyclosporine.
    Opmeer BC; Heydendael VM; De Borgie CA; Spuls PI; Bossuyt PM; Bos JD; De Rie MA
    Arch Dermatol; 2004 Jun; 140(6):685-90. PubMed ID: 15210458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of psoriasis with intermittent short course cyclosporin (Neoral). A multicentre study.
    Berth-Jones J; Henderson CA; Munro CS; Rogers S; Chalmers RJ; Boffa MJ; Norris PG; Friedmann PS; Graham-Brown RA; Dowd PM; Marks R; Sumner MJ
    Br J Dermatol; 1997 Apr; 136(4):527-30. PubMed ID: 9155952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term cyclosporin monotherapy for chronic severe plaque-type psoriasis.
    Jan V; Vaillant L; Bressieux JM; Barthélemy H; Legoux A; Steiner HG; Reigneau O
    Eur J Dermatol; 1999 Dec; 9(8):615-7. PubMed ID: 10586127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conversion of psoriasis patients from the conventional formulation of cyclosporin A to a new microemulsion formulation: a randomized, open, multicentre assessment of safety and tolerability.
    Zachariae H; Abrams B; Bleehen SS; Bräutigam M; Burrows D; Ettelt MJ; Fry L; Happle R; Haustein UF; Ganslandt J; Jung EG; Knop J; Kühne KH; Mellein B; Mørk NJ; Rogers S; Schmidt AG; Schopf RE; Sumner M; Taube KM; Weidinger G; Wurdel C; Zahn E
    Dermatology; 1998; 196(2):231-6. PubMed ID: 9568413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose, short-term ciclosporin (Neoral®) therapy is effective in improving patients' quality of life as assessed by Skindex-16 and GHQ-28 in mild to severe psoriasis patients.
    Okubo Y; Natsume S; Usui K; Amaya M; Tsuboi R
    J Dermatol; 2011 May; 38(5):465-72. PubMed ID: 21352289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial.
    Flytström I; Stenberg B; Svensson A; Bergbrant IM
    Br J Dermatol; 2008 Jan; 158(1):116-21. PubMed ID: 17986302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.